Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer

The chemokine receptor, CCR4 is a seven transmembrane G protein-coupled cell surface receptor molecule with selective expression on cells of the hematopoietic system. In adult T cell leukemia (ATL), the cell-surface expression of CCR4 on leukemic cells has been found to be nearly universal. Therefore, a CCR4-directed chimeric antigen receptor (CAR) -cell may provide an effective therapeutic against ATL.

Researchers at the National Cancer Institute (NCI), Lymphoid Malignancies Branch, developed a lentivirus-derived CAR against the CCR4 molecule. The CAR can be directed to either genetically modified autologous or to allogeneic T or natural killer (NK) -cells to develop the ATL therapy. This technology includes a method of identifying lymphoid or solid tumors that produce CCR4 mRNA and then utilizing CD3+ T cells and/or NK cells to generate genetically modified T cells and/or NK cells (autologous or allogeneic) that express the CCR4 directed CAR. The identified malignancy can then be treated with the infusion of genetically modified T/NK cells. 

The NCI seeks licensing and/or co-development of an adoptive cellular therapeutic modality that targets CCR4, which is overexpressed in certain lymphoid malignancies as well as solid tumors.

Potential Commercial Applications: Competitive Advantages:
  • Identification and treatment of CCR4 mRNA producing lymphoid or solid neoplasms
  • CCR4 putative biomarker in lung adenocarcinoma and other cancers
  • CCR4 is a more recent target for cell-based immunotherapy
  • Allogenic NK cells would enable wider use of cell-based therapies

Development Stage:
Discovery (Lead Identification)


Liyanage Perera (NCI)  ➽ more inventions...

Thomas Waldmann (NCI)  ➽ more inventions...

Kevin Conlon (NCI)  ➽ more inventions...

Pin-Yu Perera ()  ➽ more inventions...

Intellectual Property:
Application No. PCT/US2017/052437
Application No. 17778069.9
Application No. 2017332161
Application No. 3037518
Application No. 16/334,724

Perera, LP, et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.  PMID 28543380

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Phone: 240-276-5515

OTT Reference No: E-258-2016
Updated: Jun 10, 2019